RCH Retina Journal Research. Evidence. Perspective.
The Retina 5™
No. 01November 2026nAMD

Five things to know about emerging retinal evidence.

Early Neovascular AMD

Five evidence points on structural OCT and OCT angiography findings that may signal macular neovascularization before exudation develops.

nAMDThis issue
DME
RVO
+ Beyond
Age-related macular degeneration Nonexudative MNV Structural OCT OCT angiography
01

MNV may be present before exudation develops.

In age-related macular degeneration (AMD), macular neovascularization (MNV) may be present without hemorrhage or visible exudation. A structural OCT scan without fluid does not exclude a nonexudative vascular network. This distinction is especially relevant when reviewing an eye with suspicious retinal pigment epithelium (RPE) changes.[1]

A structural OCT scan without fluid does not exclude a nonexudative vascular network.
02

Nonexudative MNV has been associated with an increased risk of subsequent exudation.

In one prospective cohort, the estimated 12-month cumulative incidence of exudation was 21.1% in eyes with subclinical MNV, compared with 3.6% in eyes without detectable MNV. These estimates come from a relatively small MNV group with incomplete follow-up, so they cannot consistently predict an individual patient's risk. The authors suggested more frequent follow-up and home monitoring for eyes with detected subclinical MNV, although their study did not test whether this improves outcomes or establish an optimal interval. Retinal evaluation may also be considered according to symptoms, OCT changes and the overall clinical picture.[1]

Estimated 12-month cumulative incidence of exudation

Eyes with subclinical MNV
21.1%
Eyes without detectable MNV
3.6%

Single prospective cohort; small MNV group with incomplete follow-up. Not a predictor of individual patient risk.[1]

03

DLS and SIRE may raise suspicion of underlying MNV.

The double-layer sign (DLS) and shallow irregular RPE elevation (SIRE) are related structural OCT descriptions; neither confirms vascular flow. In Narita and colleagues' evaluation cohort of 233 eyes, 24 had SIRE on structural OCT, but only six of those 24 had MNV detected on OCT angiography (OCT-A). These results indicate that a suspicious structural sign may justify further investigation, but it does not, by itself, establish MNV.[2]

Eyes with SIRE on structural OCT (n = 24)

6 of 24
had MNV detected on OCT-A
OCT-A-detected MNV
No MNV detected on OCT-A

Evaluation cohort of 233 eyes, Narita and colleagues.[2]

04

OCT-A may help to clarify suspicious structural OCT findings.

Structural OCT shows tissue anatomy, whereas OCT-A detects signals consistent with blood flow. In a prospective cohort of 550 fellow eyes, 42 of 112 eyes with DLS had OCT-A-detected MNV, while five additional eyes had OCT-A-detected MNV without DLS, although other structural OCT abnormalities were present. Thus, DLS and OCT-A-detected MNV did not always occur together. OCT-A may be informative when structural findings leave uncertainty, particularly if detecting a flow signal consistent with MNV would affect further assessment or referral. Image quality, possible artifacts and the wider clinical picture remain important.[3]

Structural OCT

Shows tissue anatomy.

OCT angiography

Detects signals consistent with blood flow.

Fellow eyes with DLS (n = 112)

No DLS, OCT-A-detected MNV (n = 5)
42 of 112
eyes with DLS had OCT-A-detected MNV
DLS with OCT-A-detected MNV
DLS without OCT-A-detected MNV
Additional eyes: OCT-A-detected MNV without DLS (n = 5)

Prospective cohort of 550 fellow eyes.[3]

05

Symptoms and OCT changes can help guide further assessment.

Fluid-like spaces on OCT may reflect nonexudative changes, including degenerative pseudocysts and outer retinal tubulations, rather than active leakage. Comparing current and previous OCT scans alongside symptoms, visual acuity and examination findings may help identify new or evolving abnormalities.

In the cited guidance, new distortion, unexplained visual decline, hemorrhage or OCT findings suspicious for active exudation are described as reasons for prompt retinal assessment, with additional imaging not intended to delay referral when active neovascular AMD is suspected. The NICE guideline (UK) recommends urgent referral for suspected active wet AMD, although local referral pathways may differ. Suspicious nonexudative findings may also prompt further imaging or specialist review depending on the clinical context; the cited observational studies do not establish monitoring intervals for these eyes.[4-6]

RCH Evidence Lens™

The science behind the findings.

Beyond the findings: A critical appraisal of the evidence

Critical appraisal and interpretation by the RCH methodology team.

Risk of bias assessed using the QUIPS tool for prognostic studies and the QUADAS-2 tool for diagnostic accuracy studies.[7,8]

The RCH methodology team critically appraised the key studies discussed in this article, assessing each for risk of bias: features of how a study was designed, conducted or analysed that could make its results differ systematically from the truth.

Prognostic evidence · Point 02

Subclinical MNV and subsequent exudation

The evidence suggesting the prognostic value of subclinical MNV for subsequent exudation is at high risk of bias,[1] so the risk figures in point 2 should be read with caution.

  1. Timing of exudation. The study did not record exactly when exudation began; it used the date of each patient's first anti-VEGF injection as a proxy.
  2. Unmasked clinicians. The treating clinicians knew which eyes had MNV. Those patients may have been monitored more closely and started on anti-VEGF sooner, which could make exudation seem to appear earlier in this group.
  3. No adjustment for other factors. The analysis did not account for factors such as age, smoking status, AMD severity, or the duration and severity of exudative AMD in the fellow eye, so part of the link between subclinical MNV and exudation could reflect differences between the groups rather than MNV itself.
  4. Selected population. Every patient already had exudative AMD in the fellow eye, so the results may not apply to patients without neovascular AMD in either eye.
  5. Loss to follow-up. The study did not report why some patients were lost to follow-up.
High risk of bias

Diagnostic evidence · Points 03-04

SIRE and DLS as signs of underlying MNV

SIRE and DLS may point to underlying MNV,[2,3] but the evidence behind this association is at moderate risk of bias.

  1. Inconsistent assessment. Not every eye was assessed the same way: scans were read by different graders or reading centres and, in some cases, how an eye was assessed next depended on the results of the first scan.
  2. Unclear masking. For DLS, it is unclear whether the graders reading the OCT-A scans were aware of the structural OCT results.[3] If aware, spotting a DLS could have unconsciously influenced how they read the OCT-A.
  3. Imperfect reference standard. As highlighted by the study authors, MNV grading on OCT-A (the reference standard) is challenging, which may have led to incorrect classifications.
Moderate risk of bias

RCH Perspective

Taken together, the available evidence suggests that macular neovascularization can be present before exudation develops, and that structural OCT signs such as DLS and SIRE may raise suspicion of it without confirming it. OCT angiography may help clarify these findings, although image quality and possible artifacts matter, and grading MNV on OCT-A remains challenging. The link between subclinical MNV and later exudation rests mainly on a single cohort at high risk of bias, so its risk estimates are uncertain and may not apply to eyes without neovascular AMD in the fellow eye. The diagnostic studies of DLS and SIRE carry a moderate risk of bias. Monitoring intervals for eyes with nonexudative MNV have not been established; prospective studies with masked grading and adjustment for other risk factors would help clarify the question.

Table 1: Summary of the key evidence on early neovascular AMD

StudyStudy designEstimatesRisk of bias*
de Oliveira Dias 20171 Prospective cohort HR 15.2
(95% CI 4.2-55.4)MNV and exudation risk
Higha
Narita 20202 Cross-sectional; diagnostic test accuracy Sensitivity: 100%
Specificity: 92%SIRE and MNV presence
Moderateb
Thottarath 20263 Cross-sectional; diagnostic test accuracy Sensitivity: 89%**
Specificity: 86%**DLS and MNV presence
Moderateb
Risk of bias High Moderate / Unclear Low

Note: CI = confidence interval, DLS = double-layer sign, HR = hazard ratio, MNV = macular neovascularization, QUADAS-2 = Quality Assessment of Diagnostic Accuracy Studies 2, QUIPS = Quality In Prognosis Studies, SIRE = shallow irregular RPE elevation.

*Risk of bias determined using the QUIPS and QUADAS-2 tools.[7,8]   **Calculated using reported study data.

a Outcome measurement issues; no confounding adjustment.   b Unclear masking; reference standard not uniformly applied across participants.

Imaging examples

What the signs look like

Select any image to enlarge it.

Figure 1

Structural OCT examples of RPE elevation, DLS and SIRE.

These appearances may lead to further investigation but do not in themselves confirm MNV.

Source: Adapted from Csincsik et al., Ophthalmology Retina (2024), original Figure 2; selected panels cropped. Original publication: DOI. Licensed under CC BY 4.0. Changes: cropped from the original figure.

Structural OCT and OCT-A: paired examples

Both eyes show a thick DLS: only one shows OCT-A-detected MNV.

Figure 2A
MNV detected on OCT-A

Thick DLS with OCT-A detected nonexudative MNV.

(A) Infrared image and OCT B-scan showing the DLS. (B) B-scan aligned with the en face OCT-A. (C) OCT-A showing the nonexudative neovascular membrane. Yellow arrowheads mark the boundaries.

Source: Adapted from Thottarath et al., JAMA Ophthalmology (2026), original Figure 1; cropped. Original publication: DOI. Licensed under CC BY 4.0. Changes: cropped from the original figure; original title and legend removed (legend summarized above); device brand names removed from panel labels.

Figure 2B
No MNV detected on OCT-A

Thick DLS without OCT-A-detected nonexudative MNV.

(A) B-scan aligned with the en face OCT-A. (B) Infrared image and OCT B-scan showing the DLS, with yellow arrowheads marking its boundary. (C) OCT-A showing no nonexudative neovascular membrane.

Source: Adapted from Thottarath et al., JAMA Ophthalmology (2026), original Figure 2; cropped. Original publication: DOI. Licensed under CC BY 4.0. Changes: cropped from the original figure; original title and legend removed (legend summarized above); device brand names removed from panel labels.

Selected references

  1. de Oliveira Dias JR, Zhang Q, Garcia JMB, et al. Natural history of subclinical neovascularization in nonexudative age-related macular degeneration using swept-source OCT angiography. Ophthalmology. 2018;125(2):255-266. doi:10.1016/j.ophtha.2017.08.030
  2. Narita C, Wu Z, Rosenfeld PJ, et al. Structural OCT signs suggestive of subclinical nonexudative macular neovascularization in eyes with large drusen. Ophthalmology. 2020;127(5):637-647. doi:10.1016/j.ophtha.2019.11.007
  3. Thottarath S, Gurudas S, Kubravi S, Kazantzis D, Keskin AM, Sivaprasad S. Nonexudative macular neovascularization in age-related macular degeneration. JAMA Ophthalmol. 2026;144(5):405-413. doi:10.1001/jamaophthalmol.2026.0459
  4. National Institute for Health and Care Excellence (NICE). Age-related macular degeneration. Guideline NG82, section 1.4 (Diagnosis and referral). 2018. nice.org.uk/guidance/ng82
  5. Lek JJ, Caruso E, Baglin EK, et al. Interpretation of subretinal fluid using OCT in intermediate age-related macular degeneration. Ophthalmol Retina. 2018;2(8):792-802. doi:10.1016/j.oret.2018.01.005
  6. Vidal-Oliver L, Fernández-Avellaneda P, Fragiotta S, Corradetti G, Borrelli E, Dolz-Marco R. Non-exudative OCT findings in neovascular AMD. Eye (Lond). 2025;39(3):516-526. doi:10.1038/s41433-024-03461-y
  7. Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158(4):280-286. doi:10.7326/0003-4819-158-4-201302190-00009
  8. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529-536. doi:10.7326/0003-4819-155-8-201110180-00009

The Retina 5™ series

Three conditions, and beyond

Each weekly issue of The Retina 5 presents five concise evidence points, most often on one of the three conditions at the centre of RCH's evidence and education work, with occasional issues on broader retinal topics.

This issue
nAMD
Neovascular age-related macular degeneration
DME
Diabetic macular edema
RVO
Retinal vein occlusion
+ Beyond
Other retinal topics, imaging and cross-cutting evidence
“Great retinal care extends beyond treatment. It requires evidence that informs, education that empowers, research that advances, and compassion that guides every patient journey.”
The vision behind Retina Consultants of Hamilton

About this issue

Reviewed by the RCH Retina Journal Editorial Team, November 2026.

The Retina 5 is a weekly evidence series from the RCH Retina Journal by Retina Consultants of Hamilton, focused on neovascular AMD, diabetic macular edema and retinal vein occlusion, with occasional issues on broader retinal topics.

Educational information

For eye care professionals. This page summarizes published evidence for educational purposes. It is not a clinical guideline and does not set out referral or follow-up criteria.

Information provided on this page is for general educational purposes only and is not intended to replace individualized medical advice or the clinical judgment of a patient's treating healthcare professional.

Retina Consultants of Hamilton RCH Retina Journal · The Retina 5™ · RCH Evidence Lens™